Calliditas Therapeutics's total assets for Q were kr1.86B, an increase of 27.49% from the previous quarter. DE:LC8A total liabilities were kr1.52B for the fiscal quarter, a 106.79% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.